—Translational Study Data Presented at 7th
Systemic Sclerosis World Congress Confirms CCL24 is Elevated in
Diffuse Cutaneous Systemic Sclerosis Patients; High CCL24 Serum
Levels in Patients were Correlated with Greater Disease Activity
and Worse Prognosis—
—Chemomab Also Presented Data from Multiple Preclinical
Studies at the International Rheumatology Conference in
Israel Demonstrating the Potential
Therapeutic Utility of CM-101 in Systemic Sclerosis—
—Chemomab's CM-101, a CCL24 Neutralizing Antibody with
Anti-Fibrotic and Anti-Inflammatory Activity, Is Expected to Begin
a Phase 2 Trial in Systemic Sclerosis Later this Year—
TEL AVIV, Israel,
March 14, 2022
/PRNewswire/ -- Chemomab Therapeutics, Ltd. (Nasdaq: CMMB)
(Chemomab), a clinical-stage biotechnology company focused on the
discovery and development of innovative therapeutics for fibrotic
and inflammatory diseases with high unmet need, today reported two
scientific presentations last week that included preclinical and
patient sample data supporting the potential utility of its lead
therapeutic candidate, CM-101, as a novel therapy for the treatment
of systemic sclerosis (SSc).
On March 7 Chemomab Chief
Scientific Officer Dr. Adi Mor
presented "Blocking CCL24, a novel target regulating
inflammation fibrosis and endothelial damage, shows promising
potential as treatment for Systemic Sclerosis" at the biennial
International Rheumatology Conference in Israel, and on March
12 Professor Francesco Del
Galdo of the University of Leeds presented "CCL24 as a
Marker of Worse Prognosis in diffuse cutaneous SSc: a Promising
Novel Biological Target," at the 7th Systemic Sclerosis World
Congress.
Dr. Mor presented study data from experimental models and
patient samples showing that CCL24, the target for CM-101, is
overexpressed in skin and serum samples of diffuse SSc patients
compared to healthy individuals. CCL24 levels also correlated with
fibrotic biomarkers and disease progression. In a well-established
experimental mouse model of SSc, using either prevention or
therapeutic designs, CM-101 profoundly reduced skin and lung
fibrosis.
Professor Del Galdo, Susan Cheney
Professor of Experimental Medicine and Lead, Raynaud's and
Scleroderma Programme at Leeds University, presented a
translational study that used patient samples to investigate the
association between serum CCL24 levels and the activity and
progression of systemic sclerosis. Professor Del Galdo's findings support the role of CCL24
as a potential therapeutic target, demonstrating elevated serum
levels of CCL24 in diffuse cutaneous SSc (dcSSc) patients. High
CCL24 serum levels were correlated with disease activity and worse
prognosis as reflected by high fibrotic activity and deterioration
of lung function over time in a longitudinal patient cohort.
Separately, Prof. Del Galdo is
collaborating with Chemomab to elucidate the role of CCL24 in
causing the vascular damage associated with systemic sclerosis.
Professor Del Galdo said, "This
translational study is the first to demonstrate that high CCL24
levels in patients with diffuse cutaneous systemic sclerosis are
correlated with disease activity and a worse prognosis, as
reflected by high fibrotic activity and the deterioration of lung
function over time. The study data supports the role of CCL24 as a
potential therapeutic target for diffuse cutaneous SSc, and we look
forward to an upcoming Phase 2 clinical trial assessing CM-101, a
CCL24 neutralizing antibody, in systemic sclerosis patients."
Dr. Mor noted, "The growing body of data demonstrating the role
of CCL24 in the pathophysiology of systemic sclerosis further
supports our plans to assess our CCL24 neutralizing antibody,
CM-101, as a potential therapy for systemic sclerosis in a Phase 2
trial we intend to initiate later this year."
About Systemic Sclerosis
Systemic sclerosis, also
known as scleroderma, is a rare autoimmune rheumatic disease
characterized by fibrosis and inflammation of the skin, joints and
internal organs, as well as vascular abnormalities. It
predominantly affects women and is typically diagnosed when
patients are between 30 and 50 years old. It is the most lethal of
the systemic rheumatic diseases with a median survival of only 10
years. There is no approved disease modifying drug for the
condition. There currently are an estimated 100,000 systemic
sclerosis patients in the US.
About Chemomab Therapeutics Ltd.
Chemomab is a
clinical-stage biotechnology company focusing on the discovery and
development of innovative therapeutics for fibrotic and
inflammatory diseases with high unmet need. Based on the unique and
pivotal role of the soluble protein CCL24 in promoting fibrosis and
inflammation, Chemomab developed CM-101, a monoclonal antibody
designed to bind and block CCL24 activity. CM-101 has demonstrated
the potential to treat multiple severe and life-threatening
fibrotic and inflammatory diseases. It is currently in Phase 2
trials for primary sclerosing cholangitis and liver fibrosis, with
a Phase 2 trial in systemic sclerosis expected to begin in
2022.
For more information on Chemomab, visit chemomab.com.
Forward Looking Statements
This press release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act. These
forward-looking statements include, among other things, statements
regarding the clinical development pathway for CM-101; the future
operations of Chemomab and its ability to successfully initiate and
complete clinical trials and achieve regulatory milestones; the
nature, strategy and focus of Chemomab; the development and
commercial potential and potential benefits of any product
candidates of Chemomab; and that the product candidates have the
potential to address high unmet needs of patients with serious
fibrosis-related diseases and conditions. Any statements contained
in this communication that are not statements of historical fact
may be deemed to be forward-looking statements. These
forward-looking statements are based upon Chemomab's current
expectations. Forward-looking statements involve risks and
uncertainties. Because such statements deal with future events and
are based on Chemomab's current expectations, they are subject to
various risks and uncertainties and actual results, performance or
achievements of Chemomab could differ materially from those
described in or implied by the statements in this presentation,
including: risks related to Chemomab's ability to effectively
implement the revised clinical strategy and its ability to achieve
the anticipated results; risks related to the projections and
associated benefits in pursuing the contemplated changes to the
clinical strategy; risks associated with the ongoing transitions of
certain of our executive officers, including Chemomab's new Chief
Executive Officer; the uncertain and time-consuming regulatory
approval process; risks related to Chemomab's ability to correctly
manage its operating expenses and its expenses; Chemomab's plans to
develop and commercialize its product candidates, focusing on
CM-101; the timing of initiation of Chemomab's planned clinical
trials; the timing of the availability of data from Chemomab's
clinical trials including any potential delays associated with
Chemomab's contemplated revised clinical strategy; the timing of
any planned investigational new drug application or new drug
application; Chemomab's plans to research, develop and
commercialize its current and future product candidates; the
clinical utility, potential benefits and market acceptance of
Chemomab's product candidates; Chemomab's commercialization,
marketing and manufacturing capabilities and strategy; Chemomab's
ability to protect its intellectual property position; and the
requirement for additional capital to continue to advance these
product candidates, which may not be available on favorable terms
or at all. Additional risks and uncertainties relating to
Chemomab's and its business can be found under the caption "Risk
Factors" and elsewhere in Chemomab's filings and reports with the
SEC. Chemomab expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in Chemomab's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based,
except to the extent required by applicable law.
Contacts:
Media:
Barbara Lindheim
Chemomab Therapeutics
Consulting Vice President
Investor & Public Relations,
Strategic Communications
Phone: +1-917-355-9234
barbara@chemomab.com
Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
Phone: +1-917-734-7387
ir@chemomab.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/chemomab-reports-on-two-scientific-presentations-that-support-the-potential-therapeutic-utility-of-cm-101-in-systemic-sclerosis-301501644.html
SOURCE Chemomab Therapeutics, Ltd.